

Saskatoon Health Region ANTIBIOGRAM 2016

ADULT LONG TERM CARE PATIENTS - All Isolates

January 1, 2016 - December 31, 2016

ORGANISM SUSCEPTIBILITIES NOT CONTAINED IN THIS LONG TERM CARE ANTIBIOGRAM OR WITH N<30 ISOLATES SHOULD BE REFERENCED USING THE SHR ADULT IN-PATIENT ANTIBIOGRAM FOR SUGGESTED EMPIRIC COVERAGE

Longterm Care – % Susceptible

| | # Isolates tested | Penicillin PO/IV | Ampicillin/Amoxicillin | Cloxacillin | Amoxicillin-Clavulanic acid | Piperacillin-Tazobactam | Cephalixin | Cefazolin | Cefoxitin | Cefuroxime | Ceftriaxone | Ceftazidime | Meropenem | Ertapenem | Clindamycin | Azithromycin | Erythromycin | Tetracycline/Doxycycline | Ciprofloxacin | Moxifloxacin | Trimethoprim-Sulfamethoxazole | Nitrofurantoin (urine only) | Gentamicin ⁴ | Tobramycin | Vancomycin |
|--------------------------------------------|-------------------|---------------------------------------------------|------------------------|-------------|-----------------------------|-------------------------|------------|-----------|-----------|------------|-------------|-------------|-----------|-----------|-------------|--------------|--------------|--------------------------|---------------|--------------|-------------------------------|-----------------------------|-------------------------|------------|------------|
| GRAM-NEGATIVE BACTERIA | | | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Escherichia coli</i> ¹ | 756 | 41 | 78 | 94 | 64 | 85 | 74 | 74 | 100 | 100 | | | | | | | | 46 | 61 | 94 | 87 | 87 | | | |
| <i>Enterobacter aerogenes</i> ² | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Enterobacter cloacae</i> ² | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Haemophilus influenzae</i> | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Klebsiella pneumoniae</i> ¹ | 123 | R | 89 | 93 | 89 | 92 | 92 | 92 | 100 | 100 | | | | | | | | 89 | 86 | 58 | 94 | 94 | | | |
| <i>Klebsiella oxytoca</i> | 32 | R | 100 | 100 | 41 | 100 | 100 | 100 | 100 | 100 | | | | | | | | 100 | 100 | 88 | 100 | 100 | | | |
| <i>Pseudomonas aeruginosa</i> ² | 51 | R | | 90 | | | | | 88 | 94 | | | | | | | | 78 | R | R | 92 | 94 | | | |
| <i>Proteus mirabilis</i> | 139 | 93 | 99 | 100 | 93 | 96 | 99 | 100 | 100 | 100 | | | | | | | | 90 | 91 | R | 98 | 99 | | | |
| <i>Citrobacter freundii</i> ² | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Citrobacter koseri</i> ² | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Serratia marcescens</i> ² | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |

| | # Isolates tested | Penicillin PO/IV | Ampicillin/Amoxicillin | Cloxacillin | Amoxicillin-Clavulanic acid | Piperacillin-Tazobactam | Cephalixin | Cefazolin | Cefoxitin | Cefuroxime | Ceftriaxone | Ceftazidime | Meropenem | Ertapenem | Clindamycin | Azithromycin | Erythromycin | Tetracycline/Doxycycline | Ciprofloxacin | Moxifloxacin | Trimethoprim-Sulfamethoxazole | Nitrofurantoin (urine only) | Gentamicin ⁴ | Tobramycin | Vancomycin |
|---------------------------------------------------|-------------------|---------------------------------------------------|------------------------|-------------|-----------------------------|-------------------------|------------|-----------|-----------|------------|-------------|-------------|-----------|-----------|-------------|--------------|--------------|--------------------------|---------------|--------------|-------------------------------|-----------------------------|-------------------------|------------|------------|
| GRAM-POSITIVE BACTERIA | | | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Staphylococcus aureus</i> , all | | | | | | | | | | | | | | | | | | | | | | | | | |
| - methicillin-susceptible (MSSA) | 30 | | 100 | | | | | | | | | | | | 57 | 50 | 100 | 55 | 57 | 100 | 97 | 100 | | | 100 |
| - methicillin-resistant (MRSA) | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Staphylococcus epidermidis</i> | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Streptococcus pneumoniae</i> | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| Group A Streptococcus | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| Group B Streptococcus | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Streptococcus anginosus</i> group ³ | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| Viridans group streptococci | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Enterococcus</i> species (urine) ⁵ | | refer to adult in-patient nomogram for management | | | | | | | | | | | | | | | | | | | | | | | |
| <i>Enterococcus faecalis</i> , all | 194 | 100 | | | R | R | R | R | R | R | | | | | | | R | R | 55 | 56 | 99 | | | 100 | |
| <i>Enterococcus faecium</i> , all † | 23 | R | | | R | R | R | R | R | R | | | | | | | R | 29 | R | R | 33 | | | 74 | |

R - intrinsically resistant or less than 25% susceptibility

† Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH adult in/out patient antibiogram data

¹ 7.7 % of E.coli (n=58) and 4.1 % of K.pneumoniae (n=5) were +ESBL (extended spectrum beta-lactamase)

² these organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

³ Streptococcus anginosus group includes: S. anginosus, S. constellatus, S. intermedius

⁴ susceptibility to gentamicin in gram positive organisms refers to combination synergy treatment only